Aflibercept biosimilar candidate shows comparable efficacy in nAMD

The phase 3 MAGELLAN-AMD clinical trial for proposed biosimilar to Aflibercept (Eylea) FYB203 met its primary efficacy endpoint, demonstrating comparable efficacy between FYB203 and the reference medicine in patients with neovascular age-related macular degeneration (nAMD), according to a press release.

The primary endpoint measured the change in best-corrected visual acuity from baseline to after 8 weeks of treatment.

“We are delighted that our second project in the field of ophthalmology was able to impress in the clinical phase III MAGELLAN-AMD study. Given the extensive experience from FYB201, we are confident that we will also be able to make a high-quality and cost-effective biosimilar available with FYB203, thereby further expanding our strong position in the field of biosimilar development,” said Dr. Andreas Seidl, Formycon’s CSO, in the press release.

Read the full press release here.